{"DataElement":{"publicId":"5947665","version":"1","preferredName":"Laboratory Procedure Myeloma Prognostic Risk Signature Value","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins)._The result of an action._A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)_Having value for making predictions._The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable._A form of gene expression profiling that is indicative of the biological behavior of a tumor or cancer. This pattern of expression is comprised of unique clusters of genes that display differential levels of expression. The technology is based on microarray analysis and allows for accurate prognostication based upon these criteria._The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.","longName":"5947605v1.0:5947601v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"5947605","version":"1","preferredName":"Laboratory Procedure Gene Expression Profiling Outcome","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins)._The result of an action.","longName":"2543047v1.0:5947603v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5947603","version":"1","preferredName":"Microarray Analysis Outcome","preferredDefinition":"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).:The result of an action.","longName":"C18477:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Microarray Analysis","conceptCode":"C18477","definition":"Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5825538F-595B-05EE-E053-F662850AB6EE","latestVersionIndicator":"Yes","beginDate":"2017-09-01","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-09-01","modifiedBy":"ONEDATA","dateModified":"2017-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5825538F-596C-05EE-E053-F662850AB6EE","latestVersionIndicator":"Yes","beginDate":"2017-09-01","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-09-01","modifiedBy":"ONEDATA","dateModified":"2017-09-01","changeDescription":"Created for UAMS 9/1/17 CMR","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5947601","version":"1","preferredName":"Myeloma Prognostic Risk Signature Value","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)_Having value for making predictions._The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable._A form of gene expression profiling that is indicative of the biological behavior of a tumor or cancer. This pattern of expression is comprised of unique clusters of genes that display differential levels of expression. The technology is based on microarray analysis and allows for accurate prognostication based upon these criteria._The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.","longName":"5947601v1.0","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5947600","version":"1","preferredName":"Plasma Cell Myeloma Prognostic Risk Gene Signature Data Value","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001):Having value for making predictions.:The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.:A form of gene expression profiling that is indicative of the biological behavior of a tumor or cancer. This pattern of expression is comprised of unique clusters of genes that display differential levels of expression. The technology is based on microarray analysis and allows for accurate prognostication based upon these criteria.:The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.","longName":"5947600v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Prognostic","conceptCode":"C25263","definition":"Having value for making predictions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Risk","conceptCode":"C17102","definition":"The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Gene Signature","conceptCode":"C48182","definition":"A form of gene expression profiling that is indicative of the biological behavior of a tumor or cancer. This pattern of expression is comprised of unique clusters of genes that display differential levels of expression. The technology is based on microarray analysis and allows for accurate prognostication based upon these criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Data Value","conceptCode":"C49100","definition":"The information contained in a data field. It may represent a numeric quantity, a textual characterization, a date or time measurement, or some other state, depending on the nature of the attribute.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58272EC6-5101-1BF9-E053-F662850A2936","latestVersionIndicator":"Yes","beginDate":"2017-09-01","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-09-01","modifiedBy":"ONEDATA","dateModified":"2017-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58272EC6-5112-1BF9-E053-F662850A2936","latestVersionIndicator":"Yes","beginDate":"2017-09-01","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-09-01","modifiedBy":"RODGERSC","dateModified":"2017-09-01","changeDescription":"created for UAMS 9/1/17 CMR","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3029677","version":"1","longName":"UAMS Clinical Research","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812848","version":"1","longName":"UAMS New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"MyPRS","type":"Preferred Question Text","description":"MyPRS","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"582C9C51-39BA-1A00-E053-F662850A8E91","latestVersionIndicator":"Yes","beginDate":"2017-09-01","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-09-01","modifiedBy":"RODGERSC","dateModified":"2017-09-01","changeDescription":"created for UAMS 9/1/17 cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}